Sotorasib was granted FDA approval on May 28, 2021,6 followed by the European Commission's approval on January 10, 2022.7Type Small Molecule Groups Approved, Investigational Structure 3D Download Similar Structures Weight Average: 560.606 Monoisotopic: 560.234745176 Chemical Formula C30H30F2N6O3 ...
In total, 43.4% (n = 23), 35.8% (n = 19), and 9.3% (n = 5) of patients in the 960-mg sotorasib/panitumumab, 240-mg sotorasib/panitumumab, and SOC arms, respectively, continued to receive treatment after the data cutoff date. In the 960-mg sotorasib/panitumumab, 240-mg so...
LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC), as determined by an FDA‑approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated ...
months, just barely beating the LUMAKRAS’ 12.5 months. However, adagrasib is being considered by the FDA, with the decision date expected in mid-December, which still puts Mirati long behind Amgen (about 19 months). Because KRAS G12C mutation continues to multiply, researchers anticipate tha...